X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
Nitric Oxide is a guanylate cyclase activator, its novel nasal spray formulation is being evaluated for the treatment of recurrent acute rhinosinusitis.
Lead Product(s): Nitric Oxide
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
UNO (nitric oxide) is a potent molecule, naturally synthesized in the human body. It is being evaluated in phase 1 clinical trials for advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: UNO
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
eNOfit is a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: eNOfit
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
INOmax® EVOLVE™ DS delivery system has been cleared by the U.S. Food and Drug Administration for the delivery of INOmax® (nitric oxide) gas, for inhalation, for the treating neonatal patients with hypoxic respiratory failure
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOmax Evolve
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
The financing will be used to support the ongoing commercial launch of LungFit PH (nitric oxide) and advance clinical development of the LungFit platform. The Company has received FDA approval for LungFit PH for persistent pulmonary hypertension of the newborn.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LungFit
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avenue Capital Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2023
Details:
iNOPulse (nitric oxide) enters the smooth muscle cells and activates a chemical, sGC in these cells, which produces another substance called cyclic guanosine monophosphate, that causes the smooth muscle cells to relax (vasodilation) in fibrotic interstitial lung disease.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
iNOPulse (nitric oxide) enters the smooth muscle cells and activates a chemical, sGC in these cells, which produces another substance called cyclic guanosine monophosphate, that causes the smooth muscle cells to relax (vasodilation) in fibrotic interstitial lung disease.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
The proceeds will be used to complete REBUILD Phase 3 study of INOpulse delivery system for the treatment of PH-ILD. The INOpulse delivery system was designed to deliver nitric oxide in a targeted fashion allowing it to act primarily on the well-functioning part of the lung.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 06, 2023
Details:
iNOPulse (nitric oxide) enters the smooth muscle cells, it directly activates a chemical called sGC in these cells. sGC produces another substance called cyclic guanosine monophosphate. Cyclic GMP then causes the smooth muscle cells to relax, which in turn causes vasodilation.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stanford School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 24, 2023
Details:
iNOPulse (Nitric oxide) enters the smooth muscle cells, it directly activates a chemical called sGC in these cells. sGC produces another substance called cyclic guanosine monophosphate. Cyclic GMP then causes the smooth muscle cells to relax, which in turn causes vasodilation.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Bellerophon Therapeutics (nitric oxide) is developing the INOpulse delivery system for the treatment of patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD).
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INOpulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baylor BioSciences
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2023
Details:
Third Pole's technology generates pure inhaled nitric oxide (iNO) for therapeutic use and delivers it to the patient on demand, providing clinicians with greater flexibility than with iNO therapeutics stored in compressed gas cylinders.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 14, 2022
Details:
Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
LungFit PRO (Nitric Oxide) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: LungFit PRO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
LungFit PRO having nitric oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: LungFit PRO
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
INOmax® (nitric oxide) gas, for inhalation, is an FDA-approved treatment that is indicated to improve oxygenation and reduce need for extracorporeal membrane oxygenation in term and near-term neonates with hypoxic respiratory failure associated.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Inomax
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
The REBUILD study is a Phase 3, clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNOPulse) in subjects on long-term oxygen therapy who are at risk for pulmonary hypertension associated with pulmonary fibrosis.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
NONS is currently sold as a medical device under the brand name VirX™ in Thailand, Hong Kong, and Singapore and as a medical device under the brand name of enovid™ in Indonesia, Israel, and Bahrain.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VirX
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Horizons Ventures
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 24, 2022
Details:
Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect on SARS-CoV-2, the virus that causes COVID-19, and its variants.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-demand nitric oxide.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LungFit PH
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
LungFit® GO is the first Nitric Oxide generator and delivery system safely used in a clinical trial in the home setting with patients self-administering high concentration NO treatment.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: LungFit GO
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
The active substance in INOpulse (nitric oxide), is a molecule naturally produced in the endothelial lining of blood vessels that plays a significant role in vasodilation, or opening of the arteries, including arteries in the lung.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001).
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
Data from study, showed re-hospitalization rate per 100 Patient Exposure Years due to bronchiolitis related reasons trended favorably for inhaled NO group. In addition, long-term subject re-hospitalization rate for any reason was similar between inhaled NO and control groups.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard supportive treatment.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: LungFit PRO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Nitric Oxide (NO) is a powerful molecule, naturally synthesized in human body, proven to play a critical role in a broad array of biological functions. In airways, NO targets vascular smooth muscle cells that surround small resistance arteries in lungs.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
Details:
Data suggests ultra-high concentration gaseous Nitric oxide (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Phase 3 trial of Nitric oxide reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
Details:
Phase 2 result of iNOPulse (Nitric oxide) provides a clinically meaningful reduction in pulmonary vascular resistance. Treatment was safe and well-tolerated, with no treatment-emergent adverse events observed during the acute hemodynamic dose-escalation phase of the study.
Lead Product(s): Nitric Oxide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2021
Details:
Beyond Cancer, including those owned by Beyond Air, will use the proceeds from the private placement for the safety and efficacy of the ultra-high concentration nitric oxide product, as well as its therapeutic potential in a number of indications.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Beyond Air
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 18, 2021
Details:
LungFit® GO (Nitric Oxide) safely moves high concentration nitric oxide allowing patients to self administer the therapy and transform the lives of patients with respiratory conditions and severe lung infections.
Lead Product(s): Nitric Oxide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LungFit GO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Details:
Nitric Oxide Nasal Spray has been tested in healthy volunteers and patients as part of UK and Canada clinical trials. Glenmark’s exclusive long-term partnership with SaNOtize to manufacture, market and sell NONS extends.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 02, 2021
Details:
Compant will be conducting a Phase III trial on a nitric oxide nasal spray, which it claims is effective in treatment of Covid-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
Details:
The SaNOtize treatment is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
A total of 50 (90.9 percent) PT and 75 (88.2 percent) TNT neonates achieved a ≥25 percent decrease in OI/SOI during treatment with INOmax.
Lead Product(s): Nitric Oxide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: INOmax
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021
Details:
Alternative iNO delivery systems available for transport, the authors point out that only GENOSYL® Delivery System has been approved by the U.S. Food and Drug Administration (FDA) for the administration of inhaled Nitric Oxide during interhospital patient transport.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Genosyl
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
Patients with a self-administered Nitric Oxide Nasal Spray (NONS) application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
The funding will support a clinical trial to determine whether high doses of inhaled nitric oxide are safe and effective when used in conjunction with current standard-of-care therapies, including amikacin and azithromycin.
Lead Product(s): Nitric Oxide,Amikacin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Funding February 16, 2021
Details:
The SaNOtize Nitric Oxide Nasal Spray (NONS) is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2021
Details:
Independent Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 100 patients randomized in the Phase 3 COViNOX study of INOpulse® for the treatment of COVID-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Mallinckrodt has initiated a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® gas, for inhalation therapy in patients with respiratory complications associated with the COVID-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: INOmax
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The results from this first cohort established the safety of the iNO30 dose and confirmed the potential for INOpulse to provide clinically meaningful benefits in levels of daily activity in this patient population.
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
Initiation of the COViNOX Study follows the conclusion of the FDA emergency access program through which 180 patients with COVID-19 were treated in the United States.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: iNOPulse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
SaNOtize is going to study its Nitric Oxide Releasing Solution (NORSTM) in a Phase II trial for the prevention and early treatment of COVID-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
Mallinckrodt's support to Massachusetts General Hospital includes providing funding as well as INOmax® (nitric oxide) gas, for inhalation, to facilitate the study.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mallinckrodt Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 30, 2020
Details:
Research at Utah State University, confirm Sanotize's nitric oxide releasing solution (norstm) is over 99.9% effective against sars-cov-2, the virus that causes covid-19.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
IND submission follows completed treatment of several covid-19 patients with Inopulse under FDA authorized emergency expanded access program.
Lead Product(s): Nitric Oxide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
